Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Journey Medical (DERM) Debt to Equity (2020 - 2026)

Journey Medical filings provide 6 years of Debt to Equity readings, the most recent being $0.79 for Q4 2025.

  • On a quarterly basis, Debt to Equity fell 35.99% to $0.79 in Q4 2025 year-over-year; TTM through Dec 2025 was $0.79, a 35.99% decrease, with the full-year FY2025 number at $0.79, down 35.99% from a year prior.
  • Debt to Equity hit $0.79 in Q4 2025 for Journey Medical, down from $0.97 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $1988.4 in Q2 2023 to a low of -$1.28 in Q3 2021.
  • Median Debt to Equity over the past 5 years was $1.13 (2024), compared with a mean of $117.86.
  • Biggest five-year swings in Debt to Equity: surged 467596.73% in 2023 and later crashed 99.91% in 2024.
  • Journey Medical's Debt to Equity stood at $0.02 in 2021, then skyrocketed by 6843.66% to $1.34 in 2022, then tumbled by 46.42% to $0.72 in 2023, then surged by 72.53% to $1.24 in 2024, then crashed by 35.99% to $0.79 in 2025.
  • The last three reported values for Debt to Equity were $0.79 (Q4 2025), $0.97 (Q3 2025), and $1.3 (Q2 2025) per Business Quant data.